<DOC>
	<DOCNO>NCT02268526</DOCNO>
	<brief_summary>This study design test CSJ148 prevent HCMV replication stem cell transplantation .</brief_summary>
	<brief_title>Efficacy Safety Study CSJ148 Stem Cell Transplant Patients</brief_title>
	<detailed_description>This study randomize , double-blinded , placebo-controlled . 80 Patients enrol randomized CSJ148 placebo ratio 3:1 . Patients undergoing stem cell transplantation enrol study . The study consist screening period , baseline visit , approximately 3-month treatment exposure period , end-of-therapy visit , follow-up period , study completion evaluation approximately 3.5 month last dose study drug administer .</detailed_description>
	<criteria>Male female patient least 18 year age schedule undergo allogeneic bone marrow , peripheral blood stem cell , cord blood transplantation begin condition chemotherapy within 2448 hour plan dose day . Subject seropositive HCMV transplantation ; donor seropositive seronegative HCMV ( donor positive/recipient positive donor negative/recipient positive ) . Have HCMVrelated organ disease within 6 month prior enrollment . Detectable HCMV infection ( positive pp65 antigenemia plasma HCMV DNA polymerase chain reaction ( PCR ) assay prior enrollment Received follow within 30 day prior enrollment : ganciclovir , valganciclovir , foscarnet , cidofovir , acyclovir ( &gt; 25 mg/kg/day IV ) , valacyclovir ( &gt; 3 gm/day oral ) , famciclovir ( &gt; 1500 mg/day oral ) , HCMV immune globulin , immune globulin ( &gt; 500 mg/kg ) , medication antiHCMV activity . Require mechanical ventilation within 7 day prior enrollment . Received vasopressor agent hemodynamic support within 7 day prior enrollment . Impaired renal function require dialysis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Safety , efficacy , pharmacokinetics , CSJ148 , HCMV , HCMV viral load ,</keyword>
	<keyword>immunogenicity</keyword>
</DOC>